Candel Therapeutics (CADL) Debt to Equity (2020 - 2023)
Historic Debt to Equity for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $0.89.
- Candel Therapeutics' Debt to Equity rose 12998.96% to $0.89 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.89, marking a year-over-year increase of 12998.96%. This contributed to the annual value of $0.42 for FY2022, which is 474918.95% up from last year.
- As of Q3 2023, Candel Therapeutics' Debt to Equity stood at $0.89, which was up 12998.96% from $0.66 recorded in Q2 2023.
- Over the past 5 years, Candel Therapeutics' Debt to Equity peaked at $0.89 during Q3 2023, and registered a low of -$0.02 during Q4 2020.
- Over the past 4 years, Candel Therapeutics' median Debt to Equity value was $0.39 (recorded in 2022), while the average stood at $0.39.
- Its Debt to Equity has fluctuated over the past 5 years, first soared by 474918.95% in 2022, then soared by 6348.9% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Debt to Equity stood at -$0.02 in 2020, then skyrocketed by 144.43% to $0.01 in 2021, then soared by 4749.19% to $0.42 in 2022, then surged by 109.69% to $0.89 in 2023.
- Its last three reported values are $0.89 in Q3 2023, $0.66 for Q2 2023, and $0.51 during Q1 2023.